UCB is excited to exchange ideas at ACR Convergence, Nov. 3-9, 2021. Learn more about our presence at the conference and work in rheumatology from Dr. Jeffrey Stark, Head of Immunology Medical Affairs U.S.

UCB spoke with Tim, who has been living with epilepsy since 1979 while he was on active duty. His story focuses on the challenges that epilepsy brings but also shares how his new, positive outlook on life has changed the way he lives. As a member of UCB’s Epilepsy Advocate program, Tim helps to support other epilepsy patients and has been a resource for others during their journey with epilepsy.

As innovators in the healthcare industry, UCB and The Innovation and Value Initiative (IVI) believe recognizing patient voices in value assessments is important. In our recent Voices on Values series, our Head of U.S. HEOR Strategy, Edward Lee, sat down with Jennifer Bright, Executive Director at IVI to discuss how we can ensure all patient voices are captured in value assessments. Learn more about their conversation.

In order to build a world where care is more accessible to every patient, you have to put patients at the center of everything you do. UCB and The Innovation and Value Initiative (IVI) are focused on developing strategies that make patients the focal point of value assessments. Learn more about our patient centered approach from our Head of U.S. HEOR Strategy, Edward Lee, and IVI Executive Director Jennifer Bright.

UCB today announced new data from a network meta-analysis (NMA) demonstrating that bimekizumab was associated with the lowest number needed to treat (NNT) to achieve Psoriasis Area and Severity Index (PASI) 90 and PASI 100 skin clearance levels compared with 12 other approved biologic therapies used for moderate to severe plaque psoriasis within 16 weeks. These results were presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2021, October 18-21. 

UCB’s ongoing work and unwavering focus keep people living with MG at the heart of everything we do, and we are committed to finding solutions for rare diseases, like MG, with a high degree of patient need by delivering purposeful innovations and differentiated solutions, creating value that cannot be expressed in numbers alone. 

Through UCB’s Digital Business Transformation, we are committed to unleashing the power of digital innovation and enabling solutions that allow patients to live the lives they choose, now and in the future.